Lymphangioma Clinical Trial
Official title:
INST UNM 1601: Compassionate Use of BYL 719 Alpelisib
This is a compassionate use protocol of BYL719 (alpelisib) treatment for a single patient with locally advanced lymphangioma positive PI3K alpha H1047R mutation.
As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication. We plan on treating this individual patient for a tentative period of 12 weeks at which time treating physician will reevaluate the patient's clinical and radiological response and further duration of treatment will be contingent on that assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06257719 -
Clinical Characteristics of Lymphatic Malformations
|
||
| Completed |
NCT01290484 -
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05983159 -
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
|
Phase 2 |